Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "NT2"


2 mentions found


Centessa Pharmaceuticals could be at the forefront of a leading narcolepsy treatment that can send its shares soaring, according to Morgan Stanley. One of the company's drugs is ORX750 for the treatment of sleep-wake disorders, including narcolepsy type 1 and 2, or NT1 and NT2. Additionally, Centessa is developing ORX142 for the treatment of excessive daytime sleepiness, or EDS, in certain neurological, neurodegenerative and psychiatric disorders. The drug is designed to increase wakefulness, reduce cataplexy and potentially be a novel treatment for narcolepsy type 1. Given the firm's view of ORX750 as a now de-risked mechanism for treating narcolepsy, Hung modeled a higher peak market share for the treatment in NT1 by 2036.
Persons: Morgan Stanley, Jeffrey Hung, narcolepsy, Hung Organizations: Pharmaceuticals, IH, EDS Locations: NT1, NT2
Revenue: 8.77 billion yuan ($1.21 billion), vs. 9.25 billion yuan expected. 8.77 billion yuan ($1.21 billion), vs. 9.25 billion yuan expected. On a GAAP basis, the company reported a net loss of $835.1 million, or 51 cents per share. A year ago, Nio reported a net loss of 2.76 billion yuan, or 1.68 yuan per share, on revenue of 10.29 billion yuan. Nio's gross margin on vehicles for the second quarter was 6.2% in the second quarter, down from 16.7% a year ago but up from 5.1% in the first quarter of 2023.
Persons: Nio's ET5, Nio, William Bin Li Organizations: Central China International, Refinitiv . Locations: Wuhan, China, Abu Dhabi
Total: 2